Truepill turns to in-home lab testing with $75M in new funding
Summary
The company, which manages shipping and pharmacy fulfillment for direct-to-consumer brands like Hims and Nurx, recently closed a $75 million series C round. Truepill currently owns and operates six pharmacies across the U.S. Its business is designed so that companies can make API calls directly into its system for a medication to be sent from one of its facilities to a patient’s home. Though Truepill started its business with lower-risk areas, such as managing medications for hair loss, he said this new capability should help its partners cover more chronic diseases. “We’re thrilled to be working with Truepill as they advance their bold vision, expand their platform and shape the future of healthcare,” Annie Lamont a managing partner at Oak HC/FT, said in a news release. “Their unique API-driven ecosystem is revolutionizing the way we think about patient care and the role of technology in creating a healthcare experience that endures.” Since Truepill was started in 2016, the company has made a name working with direct-to-consumer health startups.